Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesGenetic & Molecular TestingBCBSRI Ovarian Multimarker Coverage Update | OpenP…
    Ask Trek AI about this page
    DraftBlue Cross Blue Shield - Rhode IslandPolicy N/A

    Multimarker Serum Testing Related to Ovarian Cancer

    Customize your policy alerts

    Sign up for all Blue Cross Blue Shield - Rhode Island policy alerts

    Know when Blue Cross Blue Shield - Rhode Island releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Policy governs coverage and prior authorization for FDA-cleared multimarker serum tests (OVA1, Overa, ROMA) used to assess malignancy risk in women with ovarian adnexal masses for Blue Cross Blue Shield - Rhode Island members.

    Policy Summary
    PayerBlue Cross Blue Shield - Rhode Island
    PolicyMultimarker Serum Testing Related to Ovarian Cancer
    Policy CodePolicy N/A
    Change TypeMaterial coverage updates (OVA1 added as medically necessary when authorized)Overa/ROMA designated not covered
    Effective Date09/01/2026
    Next Review Date06/05/2026
    Key ActionObtain online prior authorization for OVA1 via the participating-provider tool before ordering.
    SourceLink
    POLICY UPDATE CHANGES

    Effective 9/1/2026, OVA1 (CPT 81503) is considered medically necessary when online authorization criteria are met for Medicare Advantage and Commercial Products.

    Overa (0003U) and ROMA (81500) are not covered for Medicare Advantage Plans and are not medically necessary for Commercial Products for all uses.

    Prior authorization is recommended for Commercial Products via the online tool for OVA1.

    3FDA-cleared multimarker tests discussed
    09/01/2026Effective date for coverage changes
    81503

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CPT code covered when authorized (OVA1)
    81500, 0003UCPT codes not covered / not medically necessary
    1Related policy listed

    Coverage Criteria

    Medically Necessary: OVA1

    Covered when ALL of the following are met

    Medicare Advantage and Commercial Products OVA1: Effective 9/1/2026, OVA1 (Aspira Labs, CPT 81503) may be considered medically necessary when the medical criteria in the online authorization tool for participating providers are met.

    Authorization via the online tool required for participating providers

    Not Medically Necessary / Not Covered: Overa and ROMA

    All uses of Overa and ROMA are not covered/not medically necessary, including but not limited to:

    Noncovered uses: Preoperative evaluation of adnexal masses to triage for malignancy; Screening for ovarian cancer; Selecting individuals for surgery for an adnexal mass; Evaluation of individuals with clinical or radiologic evidence of malignancy; Evaluation of individuals with nonspecific signs or symptoms suggesting possible malignancy; Postoperative testing and monitoring to assess surgical outcome and/or to detect recurrent malignant disease following treatment.

    Evidence insufficient to demonstrate improvement in net health outcome

    For some self-funded employer groups that have contractually excluded expanded coverage of biomarker testing under the state mandate (R.I.G.L. §27-19-81), certain genetic testing services related to biomarker testing may be subject to a contractual exclusion. Providers should refer to the member's Benefit Booklet and related Genetic Testing Services or Proprietary Laboratory Analyses policies to determine whether a specific service is covered, not medically necessary, or excluded for that member's plan.

    If a service is determined to be not medically necessary or is a non‑covered benefit, the provider may not bill the member for that service unless the member has been informed in advance and has agreed in writing to assume financial responsibility.

    Available evidence does not demonstrate that FDA‑cleared multimarker serum tests (including Overa and ROMA) improve net health outcomes by guiding referral to gynecologic oncology or changing management to improve survival or other patient‑centered outcomes. OVA1 is the only test in this policy designated as potentially medically necessary (when authorization criteria are met); by contrast, Overa (0003U) and ROMA (81500) are considered not covered for Medicare Advantage Plans and not medically necessary for Commercial Products because the evidence is insufficient to show improvement in net health outcome.

    The policy reiterates that services found to be not medically necessary or non‑covered benefits may not be charged to the member unless the member has provided prior written agreement to accept financial responsibility.

    Covered Indications

    Coding

    Overa (OVA1 Next Generation)CPTNot Covered
    0003UOncology (ovarian) biochemical assays of five proteins (apolipoprotein A-1, CA 125 II, follicle stimulating hormone, human epididymis protein 4, transferrin), utilizing serum, algorithm reported as a likelihood score
    ROMACPTNot Covered
    81500Oncology (ovarian), biochemical assays of two proteins (CA-125 and HE4), utilizing serum, with menopausal status, algorithm reported as a risk score
    OVA1CPTCovered
    81503Oncology (ovarian), biochemical assays of five proteins (CA-125, apolipoprotein A1, beta-2-microglobulin, transferrin, and pre-albumin), utilizing serum, algorithm reported as a risk score
    CA-125 referral thresholds — menopausal and premenopausal threshold notes
    Postmenopausal CA-125 threshold35 U/mL
    Premenopausal CA-125 prior guidance>200 U/mL (prior expert-opinion guidance); current guidance recommends using very elevated CA-125 together with other clinical factors rather than a fixed threshold
    Clinical factors to consider with CA-125Ultrasound findings, ascites, nodular or fixed pelvic mass, evidence of abdominal or distant metastasis

    Provider Actions and Authorization

    Prior Authorization

    Prior authorization recommended for OVA1 (CPT 81503)

    Prior authorization is recommended for OVA1 (CPT 81503) for Commercial Products via the online tool for participating providers; effective 9/1/2026 OVA1 is considered medically necessary when the medical criteria in the online authorization tool are met.

    • Test: OVA1 (Aspira Labs) — CPT 81503
    • Commercial Products: prior authorization recommended via online tool
    • Effective date for medical necessity when authorized: 9/1/2026
    Documentation Required

    Verify member benefits and eligibility

    Verify the member's benefits and eligibility prior to performing testing; benefits and eligibility are determined by the member's subscriber agreement, member certificate, and/or employer agreement—contact the provider call center for member-specific details.

    Not Covered / Not Medically Necessary

    All uses of Overa (CPT 0003U) and ROMA (CPT 81500) are not covered for Medicare Advantage Plans and are not medically necessary for Commercial Products for any indication, including but not limited to preoperative triage of adnexal masses, screening, selection for surgery, evaluation of suspected malignancy, evaluation of nonspecific symptoms, and postoperative monitoring.

    This document portion does not list additional specific molecular or genetic tests as not covered beyond those named (Overa and ROMA). Providers should consult the applicable Benefit Booklet and related policies for any plan‑specific exclusions or additional noncovered tests.

    Background

    Epithelial ovarian cancer refers to high‑grade serous epithelial ovarian, fallopian tube, and peritoneal carcinomas grouped together because of shared pathogenesis and clinical features. Most adnexal masses are benign, and definitive diagnosis requires surgical evaluation. Multimarker serum tests (OVA1, Overa, ROMA) are intended as adjuncts to clinical assessment to help triage adnexal masses, but they are not a substitute for surgical diagnosis or for evaluation by a gynecologic oncologist when malignancy is suspected.

    Definitions

    Epithelial ovarian cancer definition — groups high-grade serous ovarian, fallopian tube, and peritoneal carcinomas
    DefinitionEpithelial ovarian cancer collectively includes high-grade serous epithelial ovarian, fallopian tubal, and peritoneal carcinomas due to shared pathogenesis, presentation, and treatment.
    Clinical relevanceGrouped because there is currently no serum biomarker that distinguishes between these carcinoma types.
    Implication for testingTests and referral criteria apply to this collective group when assessing adnexal masses for malignancy risk.
    OVA1 / multivariate index assay — FDA-cleared multimarker blood test description and citations
    Test descriptionOVA1 — an FDA-cleared multivariate index assay (multimarker blood test) intended to help predict malignancy in women with an adnexal mass; FDA 510(k) summaries and clinical performance studies cited.
    Policy Summary
    PayerBlue Cross Blue Shield - Rhode Island
    PolicyMultimarker Serum Testing Related to Ovarian Cancer
    Policy CodePolicy N/A
    Change TypeMaterial coverage updates (OVA1 added as medically necessary when authorized)Overa/ROMA designated not covered
    Effective Date09/01/2026
    Next Review Date06/05/2026
    Key ActionObtain online prior authorization for OVA1 via the participating-provider tool before ordering.
    SourceLink
    On This Page
    Coverage CriteriaCovered IndicationsCodingProvider Actions and AuthorizationNot Covered / Not Medically NecessaryBackgroundDefinitions
    • Check subscriber/member certificate and employer agreement for covered benefits
    • Contact BCBSRI provider call center for member-specific benefit details
    Documentation Required

    Ordering physician must own authorization and appeals

    Ordering physicians must be directly involved in the authorization, appeal, and other administrative processes related to prior authorization/medical necessity; laboratories or third parties must not obtain authorizations on the physician’s behalf.

    • Laboratories and third parties are prohibited from obtaining or participating in authorization on behalf of the ordering physician
    • Violations may result in severe action, up to termination from the BCBSRI provider network
    Denial Risk

    Labs/third parties cannot obtain or facilitate authorization

    Do not allow laboratories or their representatives to facilitate any portion of the authorization process or any appeal; if a laboratory or third party supports the authorization process improperly, BCBSRI will deem it a policy violation and take severe action.

    • Prohibition includes preparation of documentation of clinical appropriateness or facilitating appeals
    • Noncompliant actions may lead to termination from the BCBSRI provider network
    Documentation Required

    Authorization ownership — ordering physician responsibility

    Only the ordering physician shall be involved in authorization, appeal, or other administrative processes related to prior authorization/medical necessity; laboratories or third parties must not obtain authorization on the physician’s behalf.

    • Ordering physician responsibility includes initiation and management of authorization and appeals
    • Laboratories may not act as the ordering physician’s representative in these processes
    Documentation Required

    Check member-specific benefits and eligibility

    Providers must check the member's subscriber agreement or member certificate and/or employer agreement to determine member-specific benefits and eligibility; contact the provider call center for benefit specifics.

    • Verify coverage specifics before ordering tests
    • Member agreements supersede policy language for benefit determinations
    Billing Rule

    Unauthorized laboratory services will be denied and not billable to member

    If a laboratory provides a laboratory service that has not been authorized, the service will be denied and will be the financial liability of the participating laboratory; such services may not be billed to the member.

    • Unauthorized lab-performed services will be denied as the lab’s financial liability
    • Do not attempt to bill the member for unauthorized lab services
    Denial Risk

    Risk of provider financial liability for non‑covered or not medically necessary services

    Services determined to be not medically necessary or that are non-covered benefits may not be charged to the member unless the member has been informed and has agreed in writing in advance to continue at their own expense; verify participation agreement provisions.

    • Obtain prior written agreement from the member before charging for non-covered or not medically necessary services
    • Refer to provider participation agreements for applicable provisions
    Step Therapy

    Ordering physician must manage authorization and appeals — labs/third parties prohibited

    The ordering physician must be involved in authorization and appeals; laboratories or third parties cannot obtain authorization on the physician’s behalf and must not participate in the authorization or appeal processes.

    • Ordering physician responsible for authorization and subsequent appeals
    • Laboratories/third parties are prohibited from obtaining or facilitating authorizations
    Markers and output
    Multimarker assay combining multiple serum proteins and reporting an algorithmic likelihood or risk score.
    Key referencesFDA 510(k) summaries for OVA1 and OVA1 Next Generation; clinical performance studies (e.g., Moore et al., Grenache et al.).
    ROMA definition — algorithm combining biomarkers and menopausal status
    ROMA definitionRisk of Ovarian Malignancy Algorithm (ROMA) — an algorithm combining biomarkers (eg, HE4 and CA125) and menopausal status to estimate risk of ovarian malignancy.
    Intended useUsed to estimate likelihood of malignancy in women with an adnexal (pelvic) mass as an adjunct to clinical assessment.
    Supporting evidenceValidation and comparative studies cited (eg, Moore et al. 2011; Grenache et al.; multiple meta-analyses and comparative studies listed in references).